Using the BROCA Genetic Assay to Treat Breast Cancer
Jane E. Churpek, MD, describes the BROCA genetic assay, uses targeted genomic capture and next-generation sequencing to analyze a panel of 42 genes.
Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, describes the BROCA genetic assay.
The BROCA assay uses new tools called targeted genomic capture and next-generation sequencing to analyze a panel of 42 genes. Of those 42 genes, 18 are breast cancer susceptibility genes, including BRCA 1 and BRCA 2.
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
